3-Chlor-4'-methoxy-stilben | 5415-08-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-Chlor-4'-methoxy-stilben
• 英文别名: 1-Chloro-3-[2-(4-methoxyphenyl)ethenyl]benzene
• CAS: 5415-08-7
• 化学式: C₁₅H₁₃ClO
• 分子量: 244.721
• InChiKey: QVDBAMQPPFRVEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Chlor-4'-methoxy-stilben 在 溴 、 sodium bromide 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Multipathway bromination of stilbenes. Competition between carbonium and bromonium ion intermediates

  摘要：

  DOI：

  10.1021/jo00930a035
• 作为产物：
  描述：

  4-碘苯甲醚 在 palladium diacetate 、 四丁基碘化铵 、 三乙胺 、 2-(二叔丁基膦)联苯 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 120.0~130.0 ℃ 、1.5 MPa 条件下， 反应 1.16h， 生成 3-Chlor-4'-methoxy-stilben 、 1-氯-3-(1-(4-甲氧基苯基)乙烯基)苯
  参考文献：
  名称：

  苯乙烯，不对称丁苯和支链醛的流动化学合成

  摘要：

  已经开发了两种串联流化学方法。钯与乙烯气体的单催化Heck反应为官能化苯乙烯提供了有效的合成方法。通过进一步的精制，催化剂变为多功能，并进行第二次Heck反应，从而为不对称对苯二甲酸酯的合成提供了一个连续的过程。此外，苯乙烯衍生物与合成气的铑连续催化加氢甲酰化反应可提供具有良好选择性的支链醛。在线水洗和液-液分离相结合，使乙烯Heck反应可伸缩进入加氢甲酰化步骤，从而直接从芳基碘化物中直接合成支链醛。

  DOI：

  10.1002/cctc.201200778

文献信息

• Iminophosphine palladium(II) complexes: synthesis, characterization, and application in Heck cross-coupling reaction of aryl bromides
  作者：Mustafa Kemal Yılmaz、Bilgehan Güzel

  DOI：10.1002/aoc.3158

  日期：2014.7

  Palladium(II) complexes containing phosphorus and nitrogen donor atoms (iminophosphine), dichloridoN‐[2‐(diphenylphosphino)benzylidene]‐2‐trifluoromethylaniline}palladium(II) 1, dichloridoN‐[2‐(diphenylphosphino)benzylidene]‐3‐trifluoromethylaniline}palladium(II) 2, dichloridoN‐[2‐(diphenylphosphino)benzylidene]‐2‐methylaniline}palladium(II) 3, dichloridoN‐[2‐(diphenylphosphino)benzylidene]‐3‐

  含磷和氮供体原子（亚氨基膦），二氯基 N- [2-（二苯基膦基）亚苄基] -2-三氟甲基苯胺}钯（II）配合物，二氯基钯（II）1， N- [2-（二苯基膦基）亚苄基] -3-三氟甲基苯胺}合钯（II）2，dichlorido ñ - [2-（二苯基膦基）亚苄基] -2-甲基苯胺}合钯（II）3，dichlorido ñ - [2-（二苯基膦基）亚苄基] -3-甲基苯胺}钯（II）4已成功合成，并通过FT-IR和NMR（1 H，31 P，19 F和13C）光谱技术。这些配合物首先在溴苯和苯乙烯的反应中进行了测试，以确定最佳的偶联反应条件，然后成功地用作活化和失活的芳基溴化物与苯乙烯衍生物和几种丙烯酸酯的Heck交叉偶联反应的催化剂。版权所有©2014 John Wiley＆Sons，Ltd.
• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• Novel resveratrol derivatives have diverse effects on the survival, proliferation and senescence of primary human fibroblasts
  作者：Vishal C. Birar、Angela N. Sheerin、Elizabeth L. Ostler、Richard G. A. Faragher

  DOI：10.1007/s10522-020-09896-6

  日期：2020.12

  Resveratrol alters the cytokinetics of mammalian cell populations in a dose dependent manner. Concentrations above 25-50 mu M typically trigger growth arrest, senescence and/or apoptosis in multiple different cell types. In contrast, concentrations below 10 mu M enhance the growth of log phase cell cultures and can rescue senescence in multiple strains of human fibroblasts. To better understand the structural features that regulate these effects, a panel of 24 structurally-related resveralogues were synthesised and evaluated for their capacity to activate SIRT1, as determined by an ex-vivo SIRT1 assay, their toxicity, as measured by lactate dehydrogenase release, and their effects on replicative senescence in MRC5 human fibroblasts as measured by their effects on Ki67 immunoreactivity and senescence-associated beta galactosidase activity. Minor modifications to the parent stilbene, resveratrol, significantly alter the biological activities of the molecules. Replacement of the 3,5-dihydroxy substituents with 3,5-dimethoxy groups significantly enhances SIRT1 activity, and reduces toxicity. Minimising other strong conjugative effects also reduces toxicity, but negatively impacts SIRT1 activation. At 100 mu M many of the compounds, including resveratrol, induce senescence in primary MRC5 cells in culture. Modifications that reduce or remove this effect match those that reduce toxicity leading to a correlation between reduction in labelling index and increase in LDH release. At 10 mu M, the majority of our compounds significantly enhance the growth fraction of log phase cultures of MRC5 cells, consistent with the rescue of a subpopulation of cells within the culture from senescence. SIRT1 activation is not required for rescue to occur but enhances the size of the effect.
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
• THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS
  申请人：STC. UNM

  公开号：US20160287531A1

  公开（公告）日：2016-10-06

  The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.